Marvell Technology’s planned acquisition of Lumentum Holdings will not close before the first calendar half of 2028, the company confirmed in a Tuesday communication to employees. The two businesses are expected to operate independently until then, with Marvell continuing to describe the transaction as a planned merger.
The extended timeline lands as analysts are pulling Marvell’s stock in opposite directions. TD Cowen downgraded the shares from Buy to Hold on November 3 and slashed its price target from $350 to $175, citing concerns about the structure and timing of the Lumentum deal. B. Riley Securities, by contrast, kept its Buy rating intact, though it trimmed its target to $250 from $275 on Monday and flagged the risk of delayed AI data-center spending following the election.
The Mechanics of a $115 Billion Bet
The Lumentum transaction, agreed on November 2, is an all-stock affair. Lumentum carries an implied enterprise value of $115 billion, and its shareholders are set to receive 4.5 Marvell shares for each Lumentum share they hold. Because the consideration consists entirely of Marvell equity, the company’s own valuation sits at the heart of the deal’s economics — a detail that has drawn scrutiny from investors weighing both the strategic rationale and the terms.
That scrutiny is precisely where TD Cowen planted its flag. The brokerage’s downgrade zeroed in on how the transaction is built and when it is scheduled to land, making the structure a central test of the deal’s credibility. For the acquisition to win over skeptics, Marvell will need to answer those objections convincingly — a tall order in a sector already on edge.
Two Yardsticks for the Same Stock
The broader climate has not helped. Marvell shed 2.3% in the previous session as unease over the AI sector rippled across chip names, with Reuters reporting pressure on the stock and peers following the departure of Nvidia chief Jensen Huang. Financing questions and regulatory worries across the AI space have added to the drag, leaving Marvell to sell a major transaction while investors reassess the risks of the AI trade itself.
Should investors sell immediately? Or is it worth buying Marvell Technology?
Wednesday brought a measure of relief. CoreWeave’s quarterly results and its raised revenue outlook for 2026 eased concerns about AI infrastructure spending, lifting semiconductor shares — Marvell climbed 5.5% on the day. The reprieve was short-lived: the stock gave back 0.7% on Thursday.
B. Riley’s stance offers a different lens on the same debate. Where TD Cowen focused on deal construction, B. Riley pointed to the possibility that AI data-center investments could slip, a risk it considers manageable enough to justify keeping a positive rating. The two calls frame distinct hurdles — one about how the Lumentum deal is put together, the other about the durability of AI spending — and both will shape how the equity trades in the months ahead.
Governance and a December Date
Marvell has also reshaped its board. On Wednesday it appointed Donna C. Morris, Douglas R. Bettinger and Sasan K. Goodarzi as independent directors, expanding the board from seven members to ten. Bettinger joins the audit committee, while Morris and Goodarzi sit on the compensation committee.
Investors get their next hard data point on December 1, 2026, when Marvell reports third-quarter results for fiscal 2027. A conference call is scheduled for 1:30 p.m. Pacific time. That release should give shareholders a clearer read on whether the business can bolster confidence in the Lumentum plan — or whether the deal’s structure and the sector’s jitters will keep the stock caught between two competing narratives.
Ad
Marvell Technology Stock: Buy or Sell?! New Marvell Technology Analysis from November 13 delivers the answer:
The latest Marvell Technology figures speak for themselves: Urgent action needed for Marvell Technology investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 13.
Marvell Technology: Buy or sell? Read more here...
